Table 1.
Clinical characteristics of patients with localized SN-DLBCL and SN-ENKTL
| Characteristic | All patients (n = 258), n (%) |
SN-DLBCL (n = 47), n (%) |
SN-ENKTL (n = 211), n (%) |
p(SN-DLBCL vs. SN-ENKTL) |
|---|---|---|---|---|
| Sex | ||||
| Male | 174 (67.4) | 25 (53.2) | 149 (70.6) | 0.021 |
| Female | 84 (32.6) | 22 (46.8) | 62 (29.4) | |
| Age (year) | ||||
| Median (range) | 43 (10–85) | 63 (11–82) | 40 (10–85) | <0.001 |
| ≤60 | 225 (87.2) | 25 (53.2) | 200 (94.8) | |
| >60 | 33 (12.8) | 22 (46.8) | 11 (5.2) | |
| Modified Ann Arbor stage | ||||
| Limited I | 73 (28.3) | 3 (6.4) | 70 (33.2) | 0.001 |
| Extensive I | 126 (48.8) | 32 (68.1) | 94 (44.5) | |
| II | 59 (22.9) | 12 (25.5) | 47 (22.3) | |
| Nodal involvement | ||||
| Present | 49 (19.0) | 10 (21.3) | 39 (18.5) | 0.659 |
| Absent | 209 (81.0) | 37 (78.7) | 172 (81.5) | |
| B symptoms | ||||
| Present | 104 (40.3) | 5 (10.6) | 99 (46.9) | <0.001 |
| Absent | 154 (59.7) | 42 (89.4) | 112 (53.1) | |
| LDH level | ||||
| Normal | 192 (74.4) | 37 (78.7) | 155 (73.5) | 0.514 |
| Elevated | 64 (24.8) | 10 (21.3) | 54 (25.6) | |
| Unknown | 2 (0.8) | 0 (0.0) | 2 (0.9) | |
| ECOG performance status | ||||
| 0 | 141 (54.7) | 25 (53.2) | 116 (55.0) | 0.018 |
| 1 | 94 (36.4) | 13 (27.7) | 81 (38.4) | |
| ≥2 | 23 (8.9) | 9 (19.1) | 14 (6.6) | |
| mIPI | ||||
| 0 | 126 (48.8) | 13 (27.7) | 113 (53.6) | 0.001 |
| 1 | 92 (35.7) | 20 (42.5) | 72 (34.1) | |
| 2–4 | 38 (14.7) | 14 (29.8) | 24 (11.4) | |
| Unknown | 2 (0.8) | 0 (0.0) | 2 (0.9) | |
| Treatment strategy | ||||
| CMT | 147 (57.0) | 37 (78.7) | 110 (52.1) | <0.001 |
| Chemotherapy alone | 17 (6.6) | 10 (21.3) | 7 (3.3) | |
| Radiotherapy alone | 94 (36.4) | 0 (0.0) | 94 (44.6) | |
| Response to treatment | ||||
| CR/CRu | 205 (79.5) | 36 (76.6) | 169 (80.1) | 0.686 |
| PR | 23 (8.9) | 6 (12.7) | 17 (8.1) | |
| SD | 1 (0.4) | 0 (0.0) | 1 (0.5) | |
| PD | 15 (5.8) | 2 (4.3) | 13 (6.2) | |
| Not evaluable | 14 (5.4) | 3 (6.4) | 11 (5.1) | |
SN-DLBCL sinonasal diffuse large B cell lymphoma, SN-ENKTL sinonasal extranodal NK/T cell lymphoma, LDH lactate dehydrogenase, ECOG Eastern Cooperative Oncology Group, mIPI modified International Prognostic Index, CMT combined modality therapy, CR complete response, CRu unconfirmed complete response, PR partial response, SD stable disease, PD progressive disease